# Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)

> **NCT05226169** · PHASE3 · RECRUITING · sponsor: **Asan Medical Center** · enrollment: 330 (estimated)

## Conditions studied

- Advanced Gastric Carcinoma

## Interventions

- **DRUG:** Ferinject
- **OTHER:** Conservative management

## Key facts

- **NCT ID:** NCT05226169
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-29
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05226169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05226169, "Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05226169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*